Search
Filters
Clear All
  • 9
  • 17
  • 81

Phase

  • 4
  • 3
  • 21
  • 3
  • 22
  • 1
  • 52
  • 106
  • 14
  • 107

Found 107 will-simon trials

A listing of will-simon medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin(7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin +Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome+ Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk(Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; AMyeloMATCH Clinical Trial

R
Rita Assi
18 years - 59 years
All genders
Phase 2
What is the purpose of this study?This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and …
Learn More

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

B
Bryan Schneider, MD
18 years - 100 years
All genders
Phase 3
Interventional
What is the purpose of this study?This Phase III, randomized, open-label, multicenter study will evaluate the efficacy andy of giredestrant plus everolimus compared with the physician's choice of endocrineherapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer …
Learn More

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

S
Sandeep Batra, MD
1 month - 21 years
All genders
Phase 3
Interventional
What is the purpose of this study?Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phaseutcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristined dactinomycin (VA) and examines the use …
Learn More

Evaluating Different Methods of Circulating Tumor DNA Quantification in Oncology Patients

T
Tim Lautenschlaeger, MD
18 years - 100 years
Accepts healthy volunteer
All genders
What is the purpose of this study?This study aims to invent a test that can see tiny pieces from people with cancer (specifically DNA from a person’s cancer) in blood and urine better than tests that can currently be done. In the future, this test can possibly be used to …
Learn More

Cardiovascular Health Study in Testicular Cancer Survivors

N
Nabil Adra, MD
18 years - 100 years
Male
The purpose of this study is to investigate the long-term effects of chemotherapy and bone marrow transplant on the heart health of testicular cancer survivors. Testicular cancer often affects young adult males, and the treatment can include chemotherapy with platinum-based drugs. This study looks at changes in cholesterol, hormones, and …
Learn More

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

S
Sherif Farag, MD
All genders
Observational
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and otherdications.
Learn More

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

J
Jessica Parker Metter
18 years - 100 years
Female
Phase 3
Interventional
What is the purpose of this study?The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer …
Learn More
101 - 107 of 107